论文部分内容阅读
Objective To study effects of Jiangtang Fanglong Wan (glucose-lowering and deafness-preventing capsule) on hearing in an animal model of diabetes. Methods Wistar rats were used to create a diabetes model by intraperitoneal injection of streptozotocin (STZ, 55 mg/kg). Forty rats were randomly selected to receive Jiangtang Fanglong Wan (10 g/kg/day) through intragastric gavage (treatment group) or normal saline (control group). Auditory brainstem responses (ABRs) were recorded at Months 1, 2 and 3. Results ABR latencies and wave intervals were similar between the two groups at Month 1 (P > 0.05). ABR latencies and wave intervals were shorter in the treatment group than those of the control group at Months 2 and 3 (P < 0.05 and P < 0.01, respectively). Conclusion Our results suggest that Jiangtang Fanglong Wan may have a beneficial effect in preventing and treating hearing impairment associated with diabetes.
Objective To study effects of Jiangtang Fanglong Wan (glucose-lowering and deafness-preventing capsule) on hearing in an animal model of diabetes. Methods Wistar rats were used to create a diabetes model by intraperitoneal injection of streptozotocin (STZ, 55 mg / kg) Forty rats were randomly selected to receive Jiangtang Fanglong Wan (10 g / kg / day) through intragastric gavage (treatment group) or normal saline (control group). Auditory brainstem responses (ABRs) were recorded at Months 1, 2 and 3. Results ABR latencies and wave intervals were similar between the two groups at Month 1 (P> 0.05). ABR latencies and wave intervals were shorter in the treatment group than those of the control groups at Months 2 and 3 (P <0.05 and P < 0.01, respectively). Conclusion Our results suggest that Jiangtang Fanglong Wan may have a beneficial effect in preventing and treating hearing impairment associated with diabetes